A European Medicines Agency committee now recommends withdrawing marketing authorization for Tavneos, an Amgen drug marketed in Europe by a CSL Limited subsidiary. Meanwhile, an FDA proposal to withdraw the drug from the U.S. market is set to go to a hearing.
The post EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks appeared first on MedCity News.
npm now freezes high-impact accounts after risky account changes – Aikido Security
npm now freezes high-impact accounts after risky account changes Aikido Security
